Key facts
- It has raised $19.6M; the latest was Early Stage VC ($12.3M) in Dec 2025.
- Notable investors include Qiming Venture Partners, YuanBio Venture Capital, Tsinghua Capital, Cathay Capital, Chengdu Venture Capital Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Yanshengchao
- ·The full record, as it builds
Funding rounds
No funding rounds for Yanshengchao are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yanshengchao
Developer of new drugs designed to target tumors or the immune system. The company's therapies are based on original fluid immunity research from a leading university team, enabling patients with unmet medical needs to benefit from advanced clinical applications and international collaborative opportunities.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Yanshengchao doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yanshengchao shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yanshengchao in its N-PORT filings yet. We sweep new filings monthly.